Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE